Presentation is loading. Please wait.

Presentation is loading. Please wait.

Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and.

Published byVictor Willis Modified over 6 years ago

Similar presentations

Presentation on theme: "Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and."— Presentation transcript:

1 Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and Poorer Survival  Gerard J. Oakley, MD, Simion I. Chiosea, MD  Journal of Thoracic Oncology  Volume 6, Issue 8, Pages (August 2011) DOI: /JTO.0b013e31821d41af Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A–C, Representative cases of EGFR exon 21 codon 858 T to G point mutations. The variation in peak heights for mutant and wild-type alleles on sequencing electropherograms (SEs) is shown. Portions of the SE surrounding the point mutation (arrows) were scanned. The top row represents the nucleotide sequence of the dominant polymerase chain reaction product, as recognized by the sequencing software (“GGCKGGC,” where “K” stands for a nucleotide unrecognized by the software due to the colocation of two nucleotides). Each of the four nucleotides was labeled with a unique fluorescent dye (e.g., T = thymidine, A = adenosine). A, Representative case with the mutant allele peak lower than the WA peak (MA < WA). B, Representative case with the mutant allele peak approximately threefold higher than the wild-type allele peak (MA > WA). C, Representative case with the mutant allele peak approximately ninefold higher than the wild-type allele peak (MA > WA). Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31821d41af) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Correlation between the EGFR mutant and wild-type allelic ratio as determined by sequencing electropherogram (SE) and the EGFR/CEP7 ratio as determined by fluorescence in situ hybridization (Spearman's bivariate correlation test). The correlation coefficient (ρ) is and indicates a high degree of correlation (p = 0.003). Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31821d41af) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Correlation of EGFR fluorescence in situ hybridization (FISH) with the semiquantitative evaluation of sequencing electropherograms (SEs). Portions of SE surrounding the deletion points (red arrows) were scanned. The top row was typed in and represents the wild-type sequence, and the second row represents the actual sequence of the dominant polymerase chain reaction product. A, SE of a case with an EGFR exon 19 deletion and without an easily identifiable wild-type allele after the deletion point. These laboratory values belonged to a deceased 44-year-old white nonsmoking woman who presented with stage IIIb (pT2b N2) lung adenocarcinoma and developed recurrence associated with distant metastases 8 months after the initial surgery. B, EGFR FISH corresponding to the SE in 3A (EGFR/CEP7 ratio = 39). C, Mutant allele peaks are higher than the wild-type allele peaks. However, mutant allele specific imbalance is not accompanied by amplification (see panel D). D, The EGFR/CEP7 ratio is 1.1. The presence of four EGFR and CEP7 signals per nucleus indicates tetraploidy. Polysomy and amplification represent two mechanisms of mutant allele specific imbalance that are detectable by FISH. Red signal, Texas red/rhodamine—EGFR probe; green signal, fluorescein isothiocyanate—CEP7 probe; blue signal, 4′,6-diamidino-2-phenylindole—outlining the nuclei. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31821d41af) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Disease-specific survival (DSS) analysis based on the Kaplan-Meier method. A, DSS by stage: stages I–III (events [i.e., death from disease] = 6/55, 24%; estimated mean survival = 53 months, 95% CI 47–60) versus stage IV (events = 4/17, 24%; estimated mean survival = 36 months, 95% CI 24–47). B, DSS and the dosage of the EGFR mutant allele. MA < WA (mutant allele peak height lower than that of the wild-type allele; events = 4/52, 8%; estimated mean survival = 55 months, 95% CI 48–62) versus MA > WA (mutant allele peak height higher than that of the wild-type allele, EGFR mutant allele specific imbalance; events = 6/20, 33%, estimated mean survival = 37 months, 95% CI 29–45). C, To control for stage, the DSS analysis was performed in a subgroup of patients with stage I to III. MA < WA: events = 3/43, 7%; estimated mean survival = 56 months, 95% CI 50–63 versus MA > WA: events = 3/12, 25%, estimated mean survival = 34 months, 95% CI 28–39. D, To control for patient age, the DSS was analyzed in a subgroup of patients younger than 65 years. MA < WA: events = 2/21, 10%; estimated mean survival = 57 months, 95% CI 50–65 versus MA > WA: events = 5/15, 33%, estimated mean survival = 32 months, 95% CI 25–38. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31821d41af) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and."

Similar presentations

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA  Tomomi Nakamura, MD, Naoko.

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA  Tomomi Nakamura, MD, Naoko.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.

Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Volume 140, Issue 5, Pages (November 2011)

Volume 140, Issue 5, Pages (November 2011)
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.
EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma  Maria I. Toki, MD,

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma  Maria I. Toki, MD,
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.
Microdroplet Digital PCR: Detection and Quantitation of Biomarkers in Archived Tissue and Serial Plasma Samples in Patients with Lung Cancer  Fangfei.

Microdroplet Digital PCR: Detection and Quantitation of Biomarkers in Archived Tissue and Serial Plasma Samples in Patients with Lung Cancer  Fangfei.
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Microdroplet Digital PCR: Detection and Quantitation of Biomarkers in Archived Tissue and Serial Plasma Samples in Patients with Lung Cancer  Fangfei.

Microdroplet Digital PCR: Detection and Quantitation of Biomarkers in Archived Tissue and Serial Plasma Samples in Patients with Lung Cancer  Fangfei.
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.
Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Similar presentations

Ads by Google